Chinese API Maker That Sparked Global Controversy Over Impurity-Laden Heart Drugs Gets a Close-Out of its FDA Warning Letter

The FDA has closed out its three-year-old warning letter to Zhejiang Huahai Pharmaceutical’s site in Linhai, Taizhou because of corrective actions the manufacturer has undertaken.
Source: Drug Industry Daily